People: St. Jude Medical Inc (STJ)
STJ on New York Consolidated
45.15USD
24 May 2013
45.15USD
24 May 2013
Price Change (% chg)
$-0.02 (-0.04%)
$-0.02 (-0.04%)
Prev Close
$45.17
$45.17
Open
$44.86
$44.86
Day's High
$45.44
$45.44
Day's Low
$44.60
$44.60
Volume
1,085,301
1,085,301
Avg. Vol
2,435,283
2,435,283
52-wk High
$47.45
$47.45
52-wk Low
$30.25
$30.25
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Daniel Starks |
58 | 2004 | Chairman of the Board, President, Chief Executive Officer |
Donald Zurbay |
45 | 2012 | Chief Financial Officer, Vice President - Finance |
Joel Becker |
45 | 2011 | President - U.S. Division |
Frank Callaghan |
59 | 2008 | President - Cardivasular and Ablation Technologies Division |
Eric Fain |
52 | 2012 | President - Implantable Electronic Systems Division |
Denis Gestin |
49 | 2008 | President - International |
John Heinmiller |
58 | 2012 | Executive Vice President |
Michael Rousseau |
57 | 2012 | Acting Chief Marketing Officer; Group President |
Thomas Northenscold |
54 | 2007 | Vice President - Information Technology, Chief Information Officer |
Jason Zellers |
47 | 2011 | Vice President, General Counsel, Corporate Secretary |
Angela Craig |
41 | 2012 | Vice President - Global Human Resources |
Kathleen Chester |
50 | 2012 | Vice President - Global Regulatory |
Rachel Ellingson |
43 | 2012 | Vice President - Corporate Relations |
Jeff Fecho |
52 | 2012 | Vice President - Global Quality |
John Brown |
78 | 2006 | Independent Presiding Director |
Richard Devenuti |
55 | 2001 | Independent Director |
Stuart Essig |
51 | 1999 | Independent Director |
Barbara Hill |
60 | 2007 | Independent Director |
Michael Rocca |
68 | 2004 | Independent Director |
Wendy Yarno |
58 | 2002 | Independent Director |
J. Weigelt |
Senior Manager - Investor and Corporate Relations |
Biographies
| Name | Description |
|---|---|
Daniel Starks |
Mr. Daniel J. Starks is Chairman of the Board, President, Chief Executive Officer of St. Jude Medical Inc. Mr. Starks has over 27 years of medical device industry experience. Prior to joining the Company, Mr. Starks was President and Chief Executive Officer of Daig Corporation, a manufacturer of specialty cardiovascular devices that was acquired by St. Jude Medical in 1996. In 1998, Mr. Starks was named Chief Executive Officer and President of the Company’s Cardiac Rhythm Management business and in 2001 was named President and Chief Operating Officer of the Company. Mr. Starks has been a member of the St. Jude Medical Board of Directors since the Company acquired Daig Corporation in 1996. |
Donald Zurbay |
Mr. Donald J. Zurbay is Chief Financial Officer, Vice President - Finance of St. Jude Medical Inc. Mr. Zurbay joined St. Jude Medical in 2003 as Director of Finance and was later named Corporate Controller in August 2004. Before joining St. Jude Medical, Mr. Zurbay held positions at Deloitte and Touche LLP, The Valspar Corporation and PricewaterhouseCoopers LLP. Mr. Zurbay is a member of the American Institute of Certified Public Accountants and the Minnesota Society of Certified Public Accountants. He holds a B.S. in business with an emphasis in accounting from the University of Minnesota. |
Joel Becker |
Mr. Joel D. Becker is President - U.S. Division of St. Jude Medical Inc. Mr. Becker joined St. Jude Medical in 1993 as Senior Associate in Corporate Development. In 1999, he left the company to join Myocor, Inc., a venture-backed heart failure company, as Senior Vice President. Mr. Becker returned to St. Jude Medical in 2002 where he held numerous leadership positions in both Cardiovascular and Atrial Fibrillation divisions. Mr. Becker served as Senior Vice President, Marketing for the U.S. Division from February 2011 to October 2011. Prior to February 2011, Mr. Becker served as Vice President, Program Management & Business Development for the Atrial Fibrillation Division since 2004. |
Frank Callaghan |
Mr. Frank J. Callaghan is President - Cardivasular and Ablation Technologies Division of St. Jude Medical Inc. Mr. Callaghan joined St. Jude Medical as Vice President of Research and Development for the Atrial Fibrillation Division since January 2005 as part of the ESI acquisition. From 1995 to 2005, Mr. Callaghan served as Vice President of Research and Development for ESI. |
Eric Fain |
Dr. Eric S. Fain, M.D., is President - Implantable Electronic Systems Division of St. Jude Medical Inc. He became President of the St. Jude Medical Implantable Electronic Systems Division in August 2012. Previously, he was President of the Cardiac Rhythm Management Division (CRMD). Dr. Fain originally joined Ventritex, Inc. in June 1987 as Manager, Clinical Research and was Vice President, Systems Development when St. Jude Medical acquired the company in 1997. He went on to become Senior Vice President, Clinical/Regulatory Affairs for CRMD in June 1998. He was later promoted to Executive Vice President, Development and Clinical/Regulatory Affairs for CRMD in 2005 and then President, CRMD in 2007. Dr. Fain received his M.D. from Stanford University School of Medicine and holds a Sc.B. degree in applied math/biology from Brown University. |
Denis Gestin |
Mr. Denis M. Gestin is President - International of St. Jude Medical Inc. Mr. Gestin joined St. Jude Medical in 1997 as manager of cardiac rhythm management and catheter product sales in France. He was named Managing Director of St. Jude Medical France in 1999 and was promoted to Vice President, Northern Europe & Africa in 2002. He was named President of SJM Europe, Middle East, Africa and Canada in August 2004. |
John Heinmiller |
Mr. John C. Heinmiller is Executive Vice President of St. Jude Medical Inc. He has responsibility for global support and service functions including Finance, Human Resources, Legal, Information Technology, Corporate Relations and Business Development. Mr. Heinmiller was St. Jude Medical’s Chief Financial Officer (CFO) from September 1998 through August 2012. Mr. Heinmiller joined St. Jude Medical in May 1998 as Vice President, Corporate Business Development. From 1995 to 1997, Mr. Heinmiller was Vice President of Finance and Administration of Daig Corporation. Mr. Heinmiller was a member of the Board of Directors of Daig Corporation from 1993 until St. Jude Medical acquired Daig in 1996. From 1991 to 1995, Mr. Heinmiller was Vice President, Finance and CFO of Lifecore Biomedical, Inc., a medical and surgical products company. From 1986 to 1991, Mr. Heinmiller was an Audit Partner at Grant Thornton, LLP. From 1975 to 1986, Mr. Heinmiller was employed by Grant Thornton, where he served a variety of clients including several companies in the medical device field. Mr. Heinmiller holds a B.S. in business administration from The Ohio State University and is a licensed CPA. |
Michael Rousseau |
Mr. Michael T. Rousseau is Acting Chief Marketing Officer; Group President of St. Jude Medical Inc. Mr. Rousseau joined St. Jude Medical in 1999 as Senior Vice President, Cardiac Rhythm Management Global Marketing. In August 1999, Cardiac Rhythm Management Marketing and Sales were combined under his leadership. In January 2001, he was named President, U.S. Cardiac Rhythm Management Sales, and in July 2001, he was named President, U.S. Division, a position Mr. Rousseau held until January 2008, when he was promoted to Group President, initially responsible for the Company’s four product divisions. In November 2009, Mr. Rousseau’s Group President responsibilities were realigned, with the Company’s Cardiac Rhythm Management Division and U.S. Division reporting directly to him. Mr. Rousseau served as President, U.S. Division from November 2009 to October 2011. Mr. Rousseau continues to serve as Group President over the Cardiac Rhythm Management and Neuromodulation product divisions as well as the U.S. division. |
Thomas Northenscold |
Mr. Thomas R. Northenscold is Vice President - Information Technology, Chief Information Officer of St. Jude Medical Inc. Mr. Northenscold joined St. Jude Medical in 2001 as Vice President, Finance and Administration of Daig Corporation, a wholly-owned subsidiary of St. Jude Medical. In March 2003, he was named Vice President, Administration. |
Jason Zellers |
Mr. Jason A. Zellers is Vice President, General Counsel and Corporate Secretary of St. Jude Medical Inc. He joined St. Jude Medical in 2006 as Vice President and General Counsel for the International Division. In October 2011, he was appointed St. Jude Medical’s Vice President, General Counsel and Corporate Secretary. Before joining St. Jude Medical, he was a partner at Armstrong Teasdale LLP and Schiff Hardin LLP and served as Senior Counsel at GE Healthcare. |
Angela Craig |
Ms. Angela D. Craig is Vice President - Global Human Resources of St. Jude Medical Inc. In her present role, she has responsibility for the company’s human resources function worldwide. Ms. Craig joined St. Jude Medical in May 2005 and was named Vice President, Corporate Relations and Human Resources in August 2010. Prior to joining St. Jude Medical, Ms. Craig was an executive for public and investor relations and corporate affairs at Smith and Nephew plc, a medical devices company headquartered in London, England. Ms. Craig began her career as a reporter for The Commercial Appeal newspaper, based in Memphis, Tennessee. She holds a B.A. in journalism from the University of Memphis. |
Kathleen Chester |
Ms. Kathleen M. Chester is Vice President - Global Regulatory of St. Jude Medical Inc. She joined the company in 2002 and was named Senior Vice President, Regulatory Affairs & Quality for the St. Jude Medical Cardiac Rhythm Management Division in 2007. Ms. Chester became Vice President, Regulatory Affairs & Clinical Research for the Neuromodulation Division in 2011. Prior to joining St. Jude Medical, Ms. Chester held positions at Alcon, Medtronic and Sulzer Intermedics. She has more than 25 years of medical device industry experience in regulatory affairs, quality and clinical research. Ms. Chester is a graduate of Tulane University, where she earned a B.S. in biomedical engineering. |
Rachel Ellingson |
Ms. Rachel H. Ellingson is Vice President - Corporate Relations of St. Jude Medical Inc. In this role, Ms. Ellingson is responsible for investor relations, public relations, internal communications, government affairs, and corporate giving. She also serves as President of the St. Jude Medical Foundation. Previously, Ms. Ellingson served as Vice President, Corporate Communications and Investor Relations. She joined St. Jude Medical in 2010 through the acquisition of AGA Medical, where she served as Vice President of Business Development and Investor Relations. Prior to that, she spent 15 years in investment banking, most recently as a managing director with the medical device team at Bank of America. Ms. Ellingson received her undergraduate degree from the University of Rhode Island and her M.B.A in Finance from the University of Connecticut. |
Jeff Fecho |
Mr. Jeff A. Fecho is Vice President - Global Quality of St. Jude Medical Inc. Mr. Fecho joined St. Jude Medical in 2005 as Director of Quality for the Cardiovascular Division, served as Vice President of Quality for the Cardiovascular Division from 2008 to 2012. Prior to joining St. Jude Medical, he worked in research and development and quality operations for Boston Scientific, Inc. |
John Brown |
Mr. John W. Brown is Independent Presiding Director of St. Jude Medical Inc., since 2006. Mr. Brown has a unique background and skills that qualify him not only to serve on the Board, but also to act as Presiding Director. Mr. Brown served as the Chief Executive Officer of Stryker Corporation from 1977 to 2004 and as Chairman from 1980 until his retirement in 2009. During his tenure as head of Stryker, Mr. Brown turned a small medical instruments company with annual sales of $17 million and 400 employees into a global orthopedics medical device manufacturer that at the time of his retirement had annual sales of approximately $6.7 billion and over 18,000 employees. Between 1979 and 2007, Stryker increased annual per share earnings by at least 20 percent every year but two. |
Richard Devenuti |
Mr. Richard R. Devenuti is Independent Director of St. Jude Medical Inc. Mr. Devenuti is currently the President of EMC Corporation’s Information Intelligence Group (“IIG Division”), where he oversees all aspects of the IIG Division’s operations, including worldwide sales and services, channel strategy, product development, marketing, strategic business and financial initiatives, technical support and the Total Customer Experience program. Prior to this role, Mr. Devenuti served as Senior Vice President and Chief Operating Officer of the CMA Division of EMC Corporation. Prior to joining EMC, Mr. Devenuti held a variety of senior positions at Microsoft Corporation. As a result of his leadership roles with Microsoft and EMC, Mr. Devenuti has general business experience and, in particular, experience with high growth companies in a high growth industry. |
Stuart Essig |
Mr. Stuart M. Essig is Independent Director of St. Jude Medical Inc., since 1999. Mr. Essig is currently the Chairman of the Board of Directors of Integra LifeSciences Holdings Corporation, a manufacturer of medical devices and implants, a position he has held since January 2012. Prior to such role, Mr. Essig served as Integra’s Chief Executive Officer from December 1997 until January 2012 and its President from December 1997 until November 2010. In addition, he has served as a director since he joined Integra in December 1997. Prior to joining Integra, Mr. Essig supervised the medical technology practice at Goldman, Sachs & Co. as a managing director. Mr. Essig has also served on the Board of Directors of the Advanced Medical Technology Association, a trade association that represents the medical device industry. |
Barbara Hill |
Ms. Barbara B. Hill is Independent Director of St. Jude Medical Inc., since December 2007. Ms. Hill has an accomplished record with experience in the managed healthcare industry. Ms. Hill is currently an Operating Partner of Moelis Capital Partners, a private equity firm, where she focuses on healthcare-related investments and providing strategic and operating support for Moelis’ healthcare portfolio companies. She previously served as Chief Executive Officer and a member of the Board of Directors of ValueOptions, Inc., a managed behavioral health company from March 2006 to September 2010. Previously, Ms. Hill served as Chairman and Chief Executive Officer of Woodhaven Health Services, an institutional pharmacy company, and President and a member of the Board of Directors of Express Scripts, a Fortune 100 pharmacy benefits management company. |
Michael Rocca |
Mr. Michael A. Rocca is Independent Director of St. Jude Medical Inc., since March 2004. Mr. Rocca was selected to serve on the Board because of the global financial experience he attained through various senior financial and leadership positions at multinational public companies. He served as Chief Financial Officer at Mallinckrodt, Inc., a $2.7 billion manufacturer of specialty medical technology products, from 1994 until his retirement in 2000. Prior to joining Mallinckrodt, from 1966 to 1994, Mr. Rocca worked at Honeywell, Inc., where he served in a variety of finance roles, including Vice President of Finance for Honeywell Europe in Brussels, Belgium and Vice President and Corporate Treasurer. Given Mr. Rocca’s management and financial experience, including serving as the current Chairman of the Audit Committee of Hyatt Hotels Corporation and having served as the Chairman of the Audit Committee of Lawson Software, Inc., he is uniquely qualified to serve as Chairman of the Company’s Audit Committee. |
Wendy Yarno |
Ms. Wendy L. Yarno is Independent Director of St. Jude Medical Inc. Ms. Yarno has a 27 year history of demonstrated leadership in global operations, marketing and human resources in the pharmaceutical industry. She is currently an independent consultant in the life sciences industry. From September 2010 through February 2012, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company and developer of human cell-based surrogate systems for discovery and assessment of new drug compounds. Prior to this role, she served as Chief Marketing Officer of Merck & Co., Inc., a pharmaceutical company. She also has held a series of other executive positions at Merck, including General Manager of U.S. Human Health, Executive Vice President of Worldwide Human Health Marketing and Senior Vice President of Human Resources. Additionally, Ms. Yarno served as the vice president of the Women’s Health Care Franchise at Johnson & Johnson, the world’s healthcare company. |
J. Weigelt |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Daniel Starks |
6,721,810 |
Donald Zurbay |
1,686,840 |
Joel Becker |
-- |
Frank Callaghan |
-- |
Eric Fain |
2,793,170 |
Denis Gestin |
3,062,600 |
John Heinmiller |
4,564,760 |
Michael Rousseau |
4,532,040 |
Thomas Northenscold |
-- |
Jason Zellers |
-- |
Angela Craig |
-- |
Kathleen Chester |
-- |
Rachel Ellingson |
-- |
Jeff Fecho |
-- |
John Brown |
-- |
Richard Devenuti |
-- |
Stuart Essig |
-- |
Barbara Hill |
-- |
Michael Rocca |
-- |
Wendy Yarno |
-- |
J. Weigelt |
-- |
As Of 28 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Daniel Starks |
3,986,000 | 112,126,351 |
Donald Zurbay |
0 | 0 |
Joel Becker |
0 | 0 |
Frank Callaghan |
0 | 0 |
Eric Fain |
56,800 | 0 |
Denis Gestin |
35,800 | 574,590 |
John Heinmiller |
1,073,000 | 25,384,690 |
Michael Rousseau |
1,291,000 | 30,882,626 |
Thomas Northenscold |
0 | 0 |
Jason Zellers |
0 | 0 |
Angela Craig |
0 | 0 |
Kathleen Chester |
0 | 0 |
Rachel Ellingson |
0 | 0 |
Jeff Fecho |
0 | 0 |
John Brown |
0 | 0 |
Richard Devenuti |
0 | 0 |
Stuart Essig |
0 | 0 |
Barbara Hill |
0 | 0 |
Michael Rocca |
0 | 0 |
Wendy Yarno |
0 | 0 |
J. Weigelt |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DEVENUTI RICHARD R |
5,270 | $40.64 |
DEVENUTI RICHARD R |
3,650 | $40.68 |
HILL BARBARA BENTON |
3,650 | $40.68 |
ROCCA MICHAEL A |
3,650 | $40.68 |
BROWN JOHN W |
3,650 | $40.68 |
ESSIG STUART M |
3,650 | $40.68 |
DEVENUTI RICHARD R |
5,600 | $38.45 |
YARNO WENDY L |
3,650 | $40.68 |
CRAIG ANGELA D |
3,872 | $41.25 |
ESSIG STUART M |
5,600 | $38.45 |
ESSIG STUART M |
5,600 | $41.30 |
YARNO WENDY L |
5,600 | $38.45 |
YARNO WENDY L |
5,600 | $41.18 |
BECKER JOEL |
249 | $0.00 |
BECKER JOEL |
81 | $41.93 |
ELLINGSON RACHEL |
172 | $0.00 |
ELLINGSON RACHEL |
57 | $41.40 |
FAIN ERIC S |
2,743 | $42.31 |
CALLAGHAN FRANK J |
20,000 | $30.58 |
CALLAGHAN FRANK J |
20,000 | $42.24 |
ROUSSEAU MICHAEL T |
65,000 | $38.00 |
ROUSSEAU MICHAEL T |
65,000 | $42.50 |
CRAIG ANGELA D |
12,000 | $42.11 |
ROCCA MICHAEL A |
5,600 | $41.45 |
ROCCA MICHAEL A |
5,600 | $38.45 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
